Physician profile
Sofia L Aeschlimann
NPI 1447255393
$18,011.35
in general payments reported to CMS, 2019-2025
35 companies · $3,267 in 2025
The $3,267 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,920 · 2020: $1,202 · 2021: $2,462 · 2022: $2,915 · 2023: $3,211 · 2024: $3,035 · 2025: $3,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,512.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,368.06 | 2021-2025 | Caplyta |
| Abbvie INC. | $2,106.18 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,941.00 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,468.34 | 2019-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $1,387.77 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $1,343.22 | 2020-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,041.79 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $876.18 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $869.66 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $850.97 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $594.75 | 2019-2025 | Fanapt |
| Allergan, INC. | $458.51 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.93 | 2019-2024 | Trintellix |
| Neos Therapeutics, LP | $311.17 | 2019-2024 | Adzenys Xr-Odt |
| Braeburn INC. | $275.85 | 2025 | Brixadi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $249.96 | 2022-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $225.00 | 2019 | |
| Eisai INC. | $190.17 | 2020-2022 | |
| Almatica Pharma LLC | $185.24 | 2021-2025 | Loreev Xr |
| Tris Pharma INC | $149.60 | 2022-2024 | Dyanavel Xr |
| Indivior INC. | $119.80 | 2024 | Sublocade |
| Supernus Pharmaceuticals, INC. | $111.83 | 2021-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $94.45 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $88.59 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $68.13 | 2020-2021 | |
| Bausch Health US, LLC | $66.26 | 2021-2025 | Aplenzin, Wellbutrin |
| Merck Sharp & Dohme LLC | $52.77 | 2020-2021 | |
| Orexo US, INC. | $34.90 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $34.28 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $32.85 | 2019 | |
| Pear Therapeutics (US), INC. | $22.16 | 2021 | |
| Noven Therapeutics, LLC | $21.31 | 2024 | Xelstrym |
| Neuronetics, INC. | $18.02 | 2019 | |
| Alfasigma USA, INC. | $15.09 | 2022 | |
| Shire North American Group INC | $14.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Aeschlimann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.